Tag Archives: NASDAQ:KPTI

Analysts Offer Insights on Healthcare Companies: Karyopharm Therapeutics (NASDAQ: KPTI) and Intuitive Surgical (NASDAQ: ISRG)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Karyopharm Therapeutics (NASDAQ: KPTI) and Intuitive Surgical (NASDAQ: ISRG). Karyopharm Therapeutics (NASDAQ: KPTI) Canaccord Genuity analyst Arlinda Lee reiterated a Buy rating on

Karyopharm Therapeutics Receives a Buy from Canaccord Genuity

Canaccord Genuity analyst Arlinda Lee maintained a Buy rating on Karyopharm Therapeutics (NASDAQ: KPTI) today and set a price target of $22. The company’s shares opened today at $12.76. According to TipRanks.com, Lee is a 4-star analyst with an average

Analysts Are Bullish on These Healthcare Stocks: KPTI, PTLA

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Karyopharm Therapeutics (NASDAQ: KPTI), Portola Pharma (NASDAQ: PTLA) and Shire (NASDAQ: SHPG) with bullish sentiments. Karyopharm Therapeutics (NASDAQ: KPTI) In a report

RBC Capital Believes Karyopharm Therapeutics (NASDAQ: KPTI) Won’t Stop Here

In a report released yesterday, Brian Abrahams from RBC Capital reiterated a Buy rating on Karyopharm Therapeutics (NASDAQ: KPTI), with a price target of $22. The company’s shares closed yesterday at $15.29, close to its 52-week high of $15.72. According

Karyopharm Therapeutics Gets a Buy Rating from Cantor Fitzgerald

In a report released today, Mara Goldstein from Cantor Fitzgerald maintained a Buy rating on Karyopharm Therapeutics (NASDAQ: KPTI), with a price target of $18. The company’s shares opened today at $10.87. Goldstein commented: “Biogen (BIIB-N, PT $279, Covered by

H.C. Wainwright Reaffirms Their Buy Rating on Karyopharm Therapeutics

In a report released today, Edward White from H.C. Wainwright reiterated a Buy rating on Karyopharm Therapeutics (NASDAQ: KPTI), with a price target of $23. The company’s shares closed yesterday at $10.51. According to TipRanks.com, White is a 5-star analyst